Effects of repaglinide and sitagliptin on daily glucose swing and endothelial function: an open-label parallel-group randomized trial
Latest Information Update: 21 Aug 2018
At a glance
- Drugs Repaglinide (Primary) ; Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms R-GET
- 13 Aug 2018 Status changed from not yet recruiting to completed.
- 23 Nov 2015 New trial record